Some of these drugs like gefitinib, erlotinib, and crizotinib were explicitly designed to inhibit primary therapeutic targets for NSCLC like the epidermal growth factor receptor (EGFR)5, anaplastic lymphoma receptor tyrosine kinase (ALK)6 and serine/threonine-protein kinase B-Raf (BRAF)7. The gene discussed is ALK; the disease is non-small cell lung carcinoma.